FDA Grants Fast-Track Designation to CX-01 for Acute Myeloid Leukemia

CX-01, a low-anticoagulant heparin derivative, has demonstrated good rates of complete remission, rapid platelet recovery, and no serious adverse events.

Source: CancerNetwork - September 19, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news